SGN 516
Alternative Names: SGN-516Latest Information Update: 31 Jan 2025
Price :
$50 *
At a glance
- Originator SGN Nanopharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic neuropathies
Most Recent Events
- 01 Jan 2025 Preclinical trials in Diabetic neuropathies in USA (Topical) before January 2025 (SGN Nanopharma pipeline, January 2025)
- 01 Jan 2025 SGN Nanopharma plans a phase II trial for Diabetic nephropathies in USA (Topical) in Q4 2023 (SGN Nanopharma pipeline, January 2025)